Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four ...

Focuses on the OX40 pathway to offer a novel treatment approach. - Nevenibart’s efficacy is measured by attack rate reduction compared to placebo, aiming to attract both switch and newly ...

Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx ...

ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. It has been engineered with a modified Fc domain to support Fc-silencing and half-life extension.

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., ...

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against ...

KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the process that activates the immune system. Interaction between OX40-L and its binding partner OX40 have ...